Omthera Pharmaceuticals, Inc.. to Present at the 23rd Annual Piper Jaffray Health Care Conference
Published: Nov 21, 2011
BEDMINSTER, N.J., Nov. 21, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Jerry Wisler, President and Chief Executive Officer, will present a company overview at the 23rd Annual Piper Jaffray Health Care Conference on Wednesday, November 30, 2011 at 4:30pm ET at The New York Palace hotel.
About Omthera Pharmaceuticals, Inc.
Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. In March 2011, the Company initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL). In August, 2011, Omthera initiated a Phase III trial for Epanova in patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy. For more information, please visit www.omthera.com.
Omthera Media Relations:
Rx Communications Group
SOURCE Omthera Pharmaceuticals, Inc.